0001209191-23-004278.txt : 20230120
0001209191-23-004278.hdr.sgml : 20230120
20230120163201
ACCESSION NUMBER: 0001209191-23-004278
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230120
FILED AS OF DATE: 20230120
DATE AS OF CHANGE: 20230120
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ciulla Thomas
CENTRAL INDEX KEY: 0001815426
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37783
FILM NUMBER: 23541449
MAIL ADDRESS:
STREET 1: C/O CLEARSIDE BIOMEDICAL, INC.
STREET 2: 900 NORTH POINT PARKWAY, SUITE 200
CITY: ALPHARETTA
STATE: GA
ZIP: 30005
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Clearside Biomedical, Inc.
CENTRAL INDEX KEY: 0001539029
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 452437375
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: GA
ZIP: 30005
BUSINESS PHONE: 678-270-3631
MAIL ADDRESS:
STREET 1: 900 NORTH POINT PARKWAY
STREET 2: SUITE 200
CITY: ALPHARETTA
STATE: GA
ZIP: 30005
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2023-01-20
0
0001539029
Clearside Biomedical, Inc.
CLSD
0001815426
Ciulla Thomas
C/O CLEARSIDE BIOMEDICAL, INC.
900 NORTH POINT PARKWAY, SUITE 200
ALPHARETTA
GA
30005
0
1
0
0
Chief Medical Officer
Common Stock
2023-01-20
4
S
0
13700
1.47
D
291890
D
The sales reported in this Form 4 represents shares required to be sold by the Reporting Person to satisfy tax withholding obligations in connection with the settlement of restricted stock units. The sale occurred automatically to satisfy the tax withholding obligations to be funded by a "sell to cover" transaction pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.45 to $1.51 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
/s/ Mark Ballantyne, Attorney-in-Fact
2023-01-20